Market Research Reports

Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)

34pages
Published Date: 2012-01-30
 

Description




In 2009, the global Osteoporosis drug market was worth USD 6.8 billion, with Bisphosphonate class of drugs leading the market. Amgen’s Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with the Bisphosphonate drug class. However, initial uptake of Denosumab is likely to be as second-line therapy, mostly in patients who are intolerant to Bisphosphonate. 

Our research indicates that the Osteoporosis drug pipeline is going strong with various phases of clinical development. Phase III has first-in-class products such as Odanacatib, which possesses a novel mechanism of action to combat Osteoporosis. Aprela is another drug in the stage of development.

The Chinese Osteoporosis drug industry is expected to grow at a CAGR of 13.5% from 2010 to 2015. Increased prevalence of Osteoporosis among the Chinese female population is the principal growth driver of the Osteoporosis drug industry. The other key growth drivers for the Chinese Osteoporosis market include increasing elderly population, rising living standards of the Chinese people, increasing awareness and bone health education.

Geographical analysis of the Chinese Osteoporosis drug market shows that there is a huge growth potential for Osteoporosis drugs in many cities including Shanghai, Beijing, Guangzhou, and Hangzhou. 

To gain a competitive advantage, market players should develop cost-competitive drugs with easy dosage patterns, which promote bone building effectively. Large numbers of patients are unable to comply with the strict dosage schedule of traditional Osteoporosis drugs. Further research and development can address the unmet need by coming up with drugs that have a convenient dosage schedule with better efficacy and safety compared to traditional treatment of Osteoporosis.
 
After 2012, the Parathyroid Hormone and SERM Osteoporosis drug class market is expected to decline because of anticipated growth of Prolia (Denosumab), which will largely affect other drugs’ market share.

Scope and Overview
The objective of the study on “Global and China Osteoporosis Drug Industry Analysis and Forecast (2009 – 2015),” is to gain detailed market insights for the key Osteoporosis drugs market segments. The market is analyzed on the basis of growth trends, ongoing developments, market penetration and revenue share. The report also covers the strategies followed by Osteoporosis drug market players.

Segmentation & Analysis

The report segments and analyzes the Osteoporosis drug market on the basis of the following sub-categories:

Geographic Markets

  • Global
  • China
By Segment
  • Bisphosphonate Drugs
  • SERM Drugs
  • Parathyroid Hormone Drugs
  • Calcitonin Drugs
  • Denosumab Drugs

The report provides in-depth analysis of the Osteoporosis drug market size and growth forecast for each drug category, driving factors and challenges prevailing in the overall and at the micro market levels, and opportunities and future outlook for all levels.
 

Table of Contents




CHAPTER 1 EXECUTIVE SUMMARY


CHAPTER 2 CHINA OSTEOPOROSIS MARKET ANALYSIS, 2009 – 2015

2.1 MARKET OVERVIEW
2.2 50+ CHINESE POPULATION GROWTH TREND 2007 - 2050
2.3 CHINA POPULATION AGE STRUCTURE, 2010
2.4 CHINESE POPULATION WITH OSTEOPOROSIS, 2008 - 2050 (MILLION)
2.5 DRIVING FACTOR ANALYSIS OF CHINA OSTEOPOROSIS MARKET
      2.5.1 BARGAINING POWER OF CUSTOMERS: MEDIUM/HIGH
      2.5.2 BARGAINING POWER OF SUPPLIERS: LOW
      2.5.3 THREAT OF SUBSTITUTE PRODUCTS: MEDIUM
      2.5.4 THREAT OF ENTRY OF NEW COMPETITORS: LOW
      2.5.5 INTENSITY OF COMPETITIVE RIVALRY: HIGH
2.6 APPROVED OSTEOPOROSIS TREATMENT LANDSCAPE
2.7 COMPETITIVE STRATEGIES

CHAPTER 3 CHINA OSTEOPOROSIS DRUGS MARKET

3.1 MARKET OVERVIEW
3.2 CHINESE OSTEOPOROSIS MARKET ESTIMATE & FORECAST, 2009 - 2015
3.3 DRIVERS
      3.3.1 INCREASING AWARENESS OF OSTEOPOROSIS AMONG PATIENTS AS WELL AS                      PHYSICIANS
      3.3.2 IMPROVEMENT IN THE RATE OF DIAGNOSIS
      3.3.3 BABY BOOMER GENERATION AND INCREASED LIFE EXPECTANCY
      3.3.4 HEREDITARY EFFECT AND SEDENTARY LIFESTYLE
      3.3.5 SMOKING AND ALCOHOLISM
3.4 RESTRAINTS AND OPPORTUNITIES
      3.4.1 REIMBURSEMENT POLICIES
      3.4.2 PATIENT AND PHYSICIAN EDUCATION
      3.4.3 SIGNIFICANT CLINICAL UNMET NEEDS
3.5 BISPHOSPHONATE DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
3.6 SERM DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
3.7 PARATHYROID HORMONE DRUGS MARKET ANALYSIS & FORECAST, 2010 - 2015
3.8 CALCITONIN DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
3.9 DENOSUMAB DRUGS MARKET ANALYSIS: NOT COMMERCIALIZED 

CHAPTER 4 GLOBAL OSTEOPOROSIS DRUGS MARKET ANALYSIS AND FORECAST, 2009 – 2015

4.1 MARKET OVERVIEW
4.2 GLOBAL OSTEOPOROSIS MARKET ESTIMATE & FORECAST, 2009 – 2015
4.3 GLOBAL BISPHOSPHONATE DRUGS MARKET ANALYSIS & FORECAST,
2009 – 2015
4.4 GLOBAL SERM DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
4.5 GLOBAL PARATHYROID HORMONE DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
4.6 GLOBAL CALCITONIN DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
4.7 GLOBAL DENOSUMAB DRUGS MARKET ANALYSIS & FORECAST, 2010 – 2015
4.8 PIPELINE DRUGS IN OSTEOPOROSIS MARKET ANALYSIS
     4.8.1 ODANACATIB (MK 0822)
     4.8.2 APRELA (BAZEDOXIFENE) 

CHAPTER 5 RECOMMENDATION


FIG. 1 50+ CHINESE POPULATION GROWTH TRENDS 2007 – 2050, (MILLION)
FIG. 2 CHINA POPULATION AGE STRUCTURE, 2010
FIG. 3 CHINESE POPULATION WITH OSTEOPOROSIS, 2008 - 2050 (MILLION) 
FIG. 4 CHINESE OSTEOPOROSIS MARKET ESTIMATE & FORECAST, 2009 – 2015
(USD MILLION) 
FIG. 5 CHINA BISPHOSPHONATE DRUGS MARKET ESTIMATE & FORECAST,
2009 – 2015 (USD MILLION) 
FIG. 6 CHINA SERM DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015
(USD MILLION) 
FIG. 7 CHINA PARATHYROID HORMONE DRUGS MARKET ESTIMATE & FORECAST, 2010 – 2015 (USD MILLION) 
FIG. 8 CHINA CALCITONIN DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015 (USD MILLION) 
FIG. 9 GLOBAL OSTEOPOROSIS MARKET ESTIMATE & FORECAST, 2009 – 2015
(USD MILLION) 
FIG. 10 GLOBAL BISPHOSPHONATE DRUGS MARKET ESTIMATE & FORECAST,
2009 – 2015 (USD MILLION) 
FIG. 11 GLOBAL SERM DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015
(USD MILLION) 
FIG. 12 GLOBAL PARATHYROID HORMONE DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015 (USD MILLION) 
FIG. 13 GLOBAL CALCITONIN DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015 (USD MILLION) 
FIG. 14 GLOBAL DENOSUMAB DRUGS MARKET ESTIMATE & FORECAST, 2010 – 2015 (USD MILLION) 

TABLE 1 APPROVED OSTEOPOROSIS TREATMENT LANDSCAPE

Enquiry Before Buying




 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research